EUnetHTA 21 launches the second Open Call for applications from the pharmaceutical industry for five Joint Scientific Consultations (JSC) in June 2022. The Open Call will remain open from 6 June, 2022 to 31 August, 2022. These five JSC will be consultations in parallel to EMA scientific advice and hence will focus on medicinal products, […]
D5.3 on selection criteria for assessor and co-assessor of Joint Clinical Assessments is open for public consultation between March 7 and April 5, 2022, 23:59 CET.
The public consultation for EUnetHTA 21 Deliverable 5.3 on selection criteria for assessor and co-assessor of Joint Clinical Assessments (JCA) is open for public consultation between March 7 and April 5, 2022, 23:59 CET. The draft deliverable as well as the comment form will be published on the deliverable specific page at the start of […]
EUnetHTA 21 is launching the first Open Call for applications from the pharmaceutical industry for four Joint Scientific Consultations (JSC), starting in January 2022. These will be consultations in parallel to EMA scientific advice and hence will focus on medicinal products. The Open Call will remain open from 8 November, 2021 to 7 December, 2021. […]
EUnetHTA 21 Secretariat is pleased to announced that the first EUnetHTA 21 Stakeholder Kick-Off Meeting is scheduled, online, for 03.12.2021 at 10:30-12:00 CET. The meeting will entail a high-level focus and will address the following points: Introduction of the ‘new’ EUnetHTA 21 as a consortium; Our governance principles; Planned Stakeholder interaction (public consultations); Presentation of the deliverables planned over the course of […]
PTJA17 – Elivaldogene autotemcel (eli-cel) for treatment of cerebral adrenoleukodystrophy (CALD) – project plan now available
The final project plan of the relative effectiveness assessment of ‘Elivaldogene autotemcel (eli-cel) for treatment of cerebral adrenoleukodystrophy (CALD)’ is now available for access. The final assessment report will be published on 18 August, 2021. Below is the documentation provided by the Joint Assessment Authoring Team. PTJA17 – Final Project Plan
As Joint Action 3 (JA3) comes to a close, an overview of stakeholder interaction has been prepared that focusses on who our stakeholders are, the product-related progress we have made, and all related stakeholder activities through JA3. Access here: Engaging Stakeholders in Joint Action 3
The 2021 EUnetHTA Forum Welcome Guide is now available. The guide forms a comprehensive overview of EUnetHTA activities as we near completion of Joint Action 3, and is recommended reading prior to the Forum on 15 April. Follow the link, or check the ‘Get Involved’ dropdown menu on our homepage and then to ‘Events’, you’ll […]
The 2021 EUnetHTA Forum takes place online on 15th April. In advance of this, please follow the link to access the agenda for the day’s events and speakers. 2021 EUnetHTA Forum Agenda Also, if you were unable to register and still wish to do so, please contact us directly at firstname.lastname@example.org See you there! EUnetHTA […]
Recommendations for Horizon Scanning, Topic Identification, Selection and Prioritisation for European Cooperation on Health Technology Assessment now available
The final report ‘Recommendations for Horizon Scanning, Topic Identification, Selection and Prioritisation for European Cooperation on Health Technology Assessment’ is now available. The draft recommendations were under consultation during the period July–September 2018. An overview and response to the feedback during the consultation is available, together with Endpoint Evaluations for both Pharmaceuticals and Other Technologies. […]
We are pleased to publish the Winter 2020 issue of EUnetHTA Magazine, our quarterly update on HTA with input from network stakeholders. As always, we welcome your feedback so we can continue to improve how we can focus on developments in HTA. Happy reading! Click here for more.